CONTENTS:

The 64th American Society of Hematology (ASH) Annual Meeting and Exposition was held as a hybrid event in New Orleans, Louisiana, December 10-13, 2022. As usual, the meeting attracted thousands of clinicians, scientists, industry partners, and even investment analysts worldwide to share ground-breaking research in the field of hematology. Here are two of the abstracts presented at ASH. Look for additional summaries of research presented at ASH in our next edition of The Platelet News, available to all PDSA members.

• Efgartigimod Treatment in Adults with Primary Immune Thrombocytopenia
• The Relationship Between Immune Thrombocytopenia (ITP) Outcome and Obesity

CONTENTS:

PDSA’s exhibit booth at the 2022 ASH meeting in New Orleans.
(left-right: Melissa Hilsabeck, Peter Pruitt, Ken Kruse, Caroline Kruse, Jennifer DiRaimo, and Barbara Pruitt)

This year’s 64th American Society of Hematology (ASH) Annual Meeting and Exposition was held as a hybrid in-person and virtual event in New Orleans, LA, December 10-13, 2022. The meeting attracted more than 25,000 thousand clinicians, researchers, and health-care stakeholders, including the team from PDSA, to share ground-breaking research in the field of hematology. In this edition of the e-news, we report on two abstracts presented at the ASH meeting, showcasing new insights into immune thrombocytopenia (ITP).

• Cerebral Microbleeds in Children with ITP
• A Low Platelet Count in Older Adults and The Risk for a Blood Cancer

CONTENTS:

• Relationship Between Platelet Autoantibodies and Response to Corticosteroid Treatment in Adult Patients with Primary ITP
• IFNG-AS1 and GAS5 as Potential Molecular Indicators for Childhood ITP

CONTENTS:

• Immune Thrombocytopenia in Infants Compared to Toddlers
• Defining Refractory Immune Thrombocytopenia in the Pediatric Population

CONTENTS:

• (Phase 3) Clinical Trial Data of Avatrombopag for the Treatment of Adults with Immune Thrombocytopenia
• Using an ITP Quality Improvement Tool to Improve Adherence to Treatment Guidelines

In this issue, we share exciting developments in ITP presented at this year's 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, December 7-10, 2024. First, PDSA staff and members of the Pediatric ITP Consortium of North America (ICON) collaborated on research using data from our ITP Natural History Study Registry. Second, PDSA Medical Advisor, David Kuter, MD, highlights results from the LUNA clinical trial for a new drug on the horizon to treat adults and adolescents with ITP, called rilzabrutinib.

CONTENTS:

• Complementary And Alternative Medicine (CAM) Use Reported Among Individuals with Immune Thrombocytopenia (ITP): Data from The ITP Natural History Study Registry
• Results of LUNA’s Phase 3 Clinical Trial for Rilzabrutinib to Treat ITP

CONTENTS:

• Misdiagnosis of Primary Immune Thrombocytopenia (ITP) in the Community Setting and Its Association with Inherited Platelet Disorders: Reporting New Variants of Inherited Platelet Disorders
• Corticosteroids: Read about this treatment approach, mechanism of action, benefits, and side effects.

CONTENTS:

• What is the Role of T Cells in ITP
• Video: My low platelet count causes my anxiety. Is this normal?

CONTENTS:

• The Role of Genomics in ITP
• HMB in ITP

CONTENTS:

• When and Why You Should Ask For A Second Opinion
• B-Cell Depletion Therapy